Insulin glargine's main metabolic effect as metabolite M1

October 25, 2012
Insulin glargine's main metabolic effect as metabolite M1
For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration is in the form of its metabolite M1, according to a study published online Oct. 18 in Diabetes Care.

(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration is in the form of its metabolite M1, according to a study published online Oct. 18 in Diabetes Care.

To examine the concentration of plasma and its metabolites after subcutaneous dosing, Paola Lucidi, M.D., Ph.D., from the University of Perugia in Italy, and colleagues performed a 32-hour euglycemic glucose clamp study (0.4 units/kg glargine after one week of daily glargine administration) in nine patients with . A -tandem mass spectrometry assay was used to measure glargine, M1, and M2.

The researchers found that, in five out of nine patients, glargine was detected at negligible concentrations and at few time points. M1 exhibited the same pattern as traditional radioimmunoassay-measured plasma insulin and was detected in all patients. There was no detection of M2 at all.

"In conclusion, after subcutaneous injection of a therapeutic dose in glargine-treated type 2 diabetic subjects, glargine is only transiently, and at minimal concentration, detectable in plasma, whereas its metabolite M1 accounts for most (>90 percent) of the plasma insulin concentration," the authors write. "Thus, in vivo, glargine does not exert its long-acting directly as glargine but predominantly via its main metabolite M1."

Several authors disclosed financial ties to pharmaceutical companies, including sanofi-aventis, which funded the study.

Explore further: Experimental insulin drug prevents low blood sugar

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Experimental insulin drug prevents low blood sugar

June 25, 2012

An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting ...

Recommended for you

Post-biotics may help shield obese from diabetes

April 20, 2017

You've heard of pre-biotics and pro-biotics, but now you'll be hearing a lot more about post-biotics. Researchers at McMaster University have begun to identify how post-biotics, or the by-products of bacteria, lower blood ...

Diabetes continues its relentless rise

April 13, 2017

(HealthDay)—Two new studies on diabetes deliver good and bad news, but the overall message is that the blood sugar disease remains a formidable public health burden.

Researchers unravel how stevia controls blood sugar levels

April 11, 2017

What makes stevia taste so extremely sweet? And how does the sweetener keep our blood sugar level under control? Researchers at KU Leuven (University of Leuven, Belgium) have discovered that stevia stimulates a protein that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.